7LB7 | pdb_00007lb7

Joint X-ray/neutron structure of SARS-CoV-2 main protease (3CL Mpro) in complex with Telaprevir


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free: 
    0.225 (Depositor), 0.219 (DCC) 
  • R-Value Work: 
    0.204 (Depositor), 0.198 (DCC) 

  • Method: NEUTRON DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free: 
    0.228 (Depositor) 
  • R-Value Work: 
    0.216 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 7LB7

This is version 1.5 of the entry. See complete history

Literature

Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.

Kneller, D.W.Phillips, G.Weiss, K.L.Zhang, Q.Coates, L.Kovalevsky, A.

(2021) J Med Chem 64: 4991-5000

  • DOI: https://doi.org/10.1021/acs.jmedchem.1c00058
  • Primary Citation Related Structures: 
    7LB7

  • PubMed Abstract: 

    The main protease (3CL M pro ) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, is an essential enzyme for viral replication with no human counterpart, making it an attractive drug target. To date, no small-molecule clinical drugs are available that specifically inhibit SARS-CoV-2 M pro . To aid rational drug design, we determined a neutron structure of M pro in complex with the α-ketoamide inhibitor telaprevir at near-physiological (22 °C) temperature. We directly observed protonation states in the inhibitor complex and compared them with those in the ligand-free M pro , revealing modulation of the active-site protonation states upon telaprevir binding. We suggest that binding of other α-ketoamide covalent inhibitors can lead to the same protonation state changes in the M pro active site. Thus, by studying the protonation state changes induced by inhibitors, we provide crucial insights to help guide rational drug design, allowing precise tailoring of inhibitors to manipulate the electrostatic environment of SARS-CoV-2 M pro .


  • Organizational Affiliation
    • Neutron Scattering Division, Oak Ridge National Laboratory, 1 Bethel Valley Road, Oak Ridge, Tennessee 37831, United States.

Macromolecule Content 

  • Total Structure Weight: 34.51 kDa 
  • Atom Count: 2,512 
  • Modeled Residue Count: 306 
  • Deposited Residue Count: 306 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
3C-like proteinase306Severe acute respiratory syndrome coronavirus 2Mutation(s): 0 
Gene Names: rep1a-1b
EC: 3.4.22.69
UniProt
Find proteins for P0DTD1 (Severe acute respiratory syndrome coronavirus 2)
Explore P0DTD1 
Go to UniProtKB:  P0DTD1
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP0DTD1
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
SV6

Query on SV6



Download:Ideal Coordinates CCD File
B [auth A](1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(2R,3S)-1-(cyclopropylamino)-2-hydroxy-1-oxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide
C36 H55 N7 O6
FTZGWEAUHOMNIG-FJRGXGLZSA-N

Biologically Interesting Molecules (External Reference) 

1 Unique
Entity ID: 2
IDChains NameType/Class2D Diagram3D Interactions
PRD_002448 (SV6)
Query on PRD_002448
B [auth A]TELAPREVIR, bound formPeptide-like / Antiviral

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.00 Å
  • R-Value Free:  0.225 (Depositor), 0.219 (DCC) 
  • R-Value Work:  0.204 (Depositor), 0.198 (DCC) 
  • Method: NEUTRON DIFFRACTION
  • Resolution: 2.40 Å
  • R-Value Free:  0.228 (Depositor) 
  • R-Value Work:  0.216 (Depositor) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 110.558α = 90
b = 55.691β = 101.31
c = 48.808γ = 90
Software Package:
Software NamePurpose
nCNSrefinement
PHASERphasing
CrysalisProdata reduction
CrysalisProdata scaling
Mantiddata reduction
LAUENORMdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2021-01-20
    Type: Initial release
  • Version 1.1: 2021-04-21
    Changes: Database references
  • Version 1.2: 2021-05-05
    Changes: Database references
  • Version 1.3: 2024-03-13
    Changes: Data collection, Database references, Refinement description, Source and taxonomy
  • Version 1.4: 2024-04-03
    Changes: Refinement description
  • Version 1.5: 2024-11-13
    Changes: Structure summary